Edrecolomab (monoclonal antibody 17-1A) (Q77524743)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9806108%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

Edrecolomab (monoclonal antibody 17-1A) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9806108%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

author name string

J C Adkins

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9806108%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

C M Spencer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9806108%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 October 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9806108%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9806108%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9806108%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9806108%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

619-26; discussion 627-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9806108%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003495-199856040-00011

6 December 2019

exact match

0 references

cites work

Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies

1 reference

12 December 2020

IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells

1 reference

12 December 2020

Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules

1 reference

12 December 2020

Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells

1 reference

12 December 2020

Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?

1 reference

12 December 2020

Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced

1 reference

12 December 2020

Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody

1 reference

12 December 2020

Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy

1 reference

12 December 2020

The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies

1 reference

12 December 2020

Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects

1 reference

12 December 2020

Different dose regimens of the mouse monoclonal-antibody 17-1a for therapy of patients with metastatic colorectal-carcinoma

1 reference

12 December 2020

Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes

1 reference

12 December 2020

Prevention of manifest metastasis with monoclonal antibodies: A novel approach to immunotherapy of solid tumours

1 reference

12 December 2020

Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?

1 reference

12 December 2020

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

1 reference

12 December 2020

Phase I Trial of Multiple Large Doses of Murine Monoclonal Antibody CO17-1A. II. Pharmacokinetics and Immune Response1

1 reference

12 December 2020

Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A).

1 reference

12 December 2020

Tumor-associated antigen expression of primary and metastatic colon carcinomas detected by monoclonal antibody 17-1A

1 reference

12 December 2020

Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma

1 reference

12 December 2020

Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer.

1 reference

12 December 2020

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

1 reference

12 December 2020

Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients

1 reference

12 December 2020

Anti-idiotypic antibodies to monoclonal antibody CO17-1A

1 reference

12 December 2020

Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen

1 reference

12 December 2020

Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results

1 reference

12 December 2020

Binding of murine immunoglobulin to human tissues after immunotherapy with anticolorectal carcinoma monoclonal antibody

1 reference

12 December 2020

Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome--an important antitumoral effector function?

1 reference

12 December 2020

The combination of interleukin-2 and interferon alpha effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29.

1 reference

12 December 2020

Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A

1 reference

12 December 2020

A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data

1 reference

12 December 2020

Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM)

1 reference

12 December 2020

Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma

1 reference

12 December 2020